Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Qualigen Therapeutics Inc QLGN

Healthcare Biotechnology
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:QLGN)

Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares

GlobeNewswire 6 days ago

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024

GlobeNewswire November 1, 2024

Qualigen Therapeutics, Inc. Announces management changes.

GlobeNewswire September 26, 2024

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

GlobeNewswire September 20, 2024

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

GlobeNewswire September 6, 2024

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

GlobeNewswire September 5, 2024

Lifecore Biomedical Announces Cooperation Agreement with 22NW

GlobeNewswire July 1, 2024

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

GlobeNewswire May 30, 2024

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

GlobeNewswire April 16, 2024
View More News ››

Opinion & Analysis (NDAQ:QLGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:QLGN)

QLGN .... In PB mode...has to hold

$1.15 and rally or shes done
Iseneschal - March 21, 2023

QLGN..... early a.m runner in NR

Patent news
Iseneschal - March 21, 2023

QLGN ..... My chart tells me a break of $1.52

would be meaningful Needs volume  Cheers !
Iseneschal - February 1, 2023

QLGN ...mini pop on low volume

Ya never know Cheers !
Iseneschal - February 1, 2023

QLGN.....Still waiting for "something"

Get ur a$$ in gear !!!!
Iseneschal - January 24, 2023

QLGN.... NR.....What the last guy posted ; )

Cheers !
Iseneschal - January 24, 2023
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp is a Canadian company engaged in the acquisition, exploration, and development of natural ...
View More »